Open

Study on primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)

The study will test three new medicines: frexalimab, SAR442970, and rilzabrutinib. These are for treating a kidney condition called FSGS or MCD. We want to find out if these medicines are safe and if they can reduce the amount of protein in your urine.

Age & Gender

16 years ~ 75 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

You will take the study medicine and one of our team members will check your vital signs and do a check-up. We will take a small sample of your blood and ask for a urine sample. We will also do a heart test called an ECG. We will ask you about any medicines you use and ask you to fill out two short surveys.

Incentives

information provided upon request, We will pay you back for the miles you drive to participate in the study.

In-person visits:
9

Phone or online visits:
2-9

Total length of participation:
1 year and 6 months

Looking for Specific Volunteers

Able to participate:

biopsy-proven primary FSGS or primary MCD.
Protein present in urine
agreeing to use a contraceptive method

Not eligible if:

have received a transplant or are on the transplant list
pregnant/ breastfeeding
dialysis
recent cancer diagnosis

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Vimal Derebail
Medicine-Nephrology

Study Type

Clinical or Medical
Interventional

Study Topics

Kidneys and Liver

IRB Number

24-3212

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.